ASTRAZENECA PHARMACEUTICALS LP for ASTRAZENECA PHARMACEUTICALS LP

Trade (domestic/foreign) TRD

International trade issues, including free-trade agreements and negotiations Import Safety

Contacted: SENATE; Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Centers For Medicare and Medicaid Services (CMS); U.S. Agency for International Development (USAID); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Consumer Issues/Safety/Products CSP

Prescription Drug Importation FDA Globalization Act of 2009-US House FDA preemption

Contacted: U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Congressional Budget Office (CBO)

Taxation/Internal Revenue Code TAX

Tax issues, including economic stimulus legislation, repatriaion and deferral, and bilateral tax issues

Contacted: SENATE; Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); U.S. Trade Representative (USTR); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; U.S. Agency for International Development (USAID); Commerce, Dept of (DOC)

Pharmacy PHA

Direct-to-Consumer Drug Advertising Discussions regarding Funding of FDA

Contacted: Commerce, Dept of (DOC); SENATE; Centers For Medicare and Medicaid Services (CMS); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); U.S. Agency for International Development (USAID); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES

Copyright/Patent/Trademark CPT

Patent Reform and intellectual property issues Section 182 ("Special 301") briefings on global intellectual property protections Discussions regarding patent settlements (reverse payments) legislation Discussions regarding follow on biologics

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Commerce, Dept of (DOC); Congressional Budget Office (CBO); U.S. Trade Representative (USTR); U.S. Agency for International Development (USAID); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS)

Health Issues HCR

Health Care Reform S. 301 Grassley/Kohl Physician Payments Sunshine Act of 2009 Mental Health Parity 340B Program - regarding legislation that would require extension of 340B pricing to pharmacies who also serve patients who do not qualify for 340B services VA/DoD Tricare - regarding TRICARE retail rebate legislation/rulemaking Discussions regarding global access to medicines Legislation or possible legislation regarind stem cell research Discussions regarding possible opportunities to work with CMS on education and outreach efforts

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); U.S. Agency for International Development (USAID); Commerce, Dept of (DOC); U.S. Trade Representative (USTR)

Bills named: S. 301 (111th)

Medicare/Medicaid MMM

Medicaid - regarding possible increase in Medicaid base rebate; other issues regarding possible changes to Medicaid rebate program Comparative Effectiveness - regarding use of Comparative effectiveness in health care coverage and/or reimbursement Medicare - regarding "non-interfence" clause, protected classed of drugs, and Medicare Advantage

Contacted: Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); SENATE; U.S. Trade Representative (USTR); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); U.S. Agency for International Development (USAID)